From the FDA Drug Label
DESCRIPTION Each yellow capsule-shaped tablet contains 1 g Methenamine Hippurate which is the hippur Hinno acid salt of methenamine (hexamethylene tetramine). The FDA drug label does not answer the question.
From the Research
Yes, Hiprex (methenamine hippurate) can be compounded. Hiprex is typically available as 1 gram tablets, but it can be compounded into other forms like oral suspensions or custom-dise capsules if needed. Common compounding options include:
- Oral suspension: Usually 100 mg/mL or 200 mg/mL strength
- Custom-dose capsules: Ranging from 250 mg to 1000 mg per capsule Compounding may be useful for patients who have difficulty swallowing tablets or need a specific dose not available commercially. However, compounded formulations may have shorter expiration dates and potentially less stability than manufactured tablets. When compounded, Hiprex should be stored in tight, light-resistant containers at room temperature. The pH of compounded formulations should be maintained below 5.5 to preserve the active ingredient's stability and effectiveness as a urinary antiseptic. Compounding allows for personalized medication but should only be done by licensed pharmacists following proper procedures to ensure safety and efficacy, as emphasized by the study published in Cureus in 2025 1. This is crucial to minimize the risk of contamination, inaccurate potency, and other safety issues associated with compounded medications, as highlighted in the study published in Postgraduate medicine in 2014 2. Furthermore, the study published in Orphanet journal of rare diseases in 2018 3 stresses the importance of evidence-based compounding and validated standard operating procedures to ensure patient safety.
In the context of Hiprex compounding, it is essential to prioritize patient safety and adhere to strict quality control measures, as the study published in Health technology assessment in 2022 4 demonstrates the effectiveness of methenamine hippurate in preventing recurrent urinary tract infections. Additionally, the study published in BMC health services research in 2022 5 highlights the need for healthcare practitioners to be aware of the potential risks and benefits of compounded medications and to practice rational use of these medications.
Overall, compounding of Hiprex should be approached with caution, and healthcare practitioners should carefully weigh the benefits and risks of using compounded medications, as emphasized by the study published in Cureus in 2025 1. By prioritizing patient safety and adhering to strict quality control measures, healthcare practitioners can ensure the safe and effective use of compounded Hiprex.